• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by LivaNova PLC

    6/12/25 9:23:08 PM ET
    $LIVN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $LIVN alert in real time by email
    S-8 1 tm2517935d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on June 12, 2025.

     

    Registration No. 333-

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    LivaNova PLC

    (Exact name of Registrant as specified in its charter)

     

    England and Wales 98-1268150
    (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number)
       
    20 Eastbourne Terrace  
    London, United Kingdom W2 6LG
    (Address of Principal Executive Offices) (Zip Code)

     

    Second Amended and Restated LivaNova PLC 2022 Incentive Award Plan

    LivaNova PLC 2025 Director Incentive Award Plan

    (Full title of the plans)

     

    Company Secretariat

    LivaNova PLC

    c/o

    LivaNova USA, Inc.

    100 Cyberonics Blvd.

    Houston, Texas 77058

    +1 (281) 228-7200

    (Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer x Accelerated filer ¨
    Non-accelerated filer ¨ (Do not check if a smaller reporting company) Smaller reporting company ¨
      Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act of 1933 (the “Securities Act”). ¨

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This registration statement on Form S-8 (the “Registration Statement”) is being filed in order to register an additional (i) 2,200,000 ordinary shares, par value £1.00 per share (the “Ordinary Shares”), of LivaNova PLC (the “Registrant”) that may be issued under the Registrant’s Second Amended and Restated LivaNova PLC 2022 Incentive Award Plan (the “Second A&R 2022 Plan”), (ii) 2,200,000 Ordinary Shares that may become available for issuance under the Second A&R 2022 Plan as a result of outstanding awards under the Second A&R 2022 Plan being (a) forfeited, lapsed, or expired, (b) converted to shares of another company in connection with a takeover, sale, recapitalization, reorganization, merger, consolidation, split-up, spin-off, combination, exchange of shares or other similar event, (c) settled for cash (in whole or in part) or (d) repurchased by the Registrant and (iii) 300,000 Ordinary Shares that may be issued under the Registrant’s LivaNova PLC 2025 Director Incentive Award Plan.

     

    The Ordinary Shares are securities of the same class as those securities registered on the Registrant’s registration statements on Form S-8 previously filed with the Securities and Exchange Commission (the “Commission”) on June 12, 2024 (Registration No. 333-280160), July 26, 2023 (Registration No. 333-273450), June 13, 2022 (Registration No. 333-265563) and October 19, 2015 (Registration No. 333-207478) which are hereby incorporated by reference, except to the extent supplemented, amended or superseded by information set forth in this Registration Statement, consistent with General Instruction E to Form S-8.

     

    Part II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents By Reference.

     

    The following documents filed by the Registrant with the Commission are incorporated into this Registration Statement by reference:

     

      (a) the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on February 25, 2025 (including the information specifically incorporated by reference therein from the Registrant’s definitive proxy statement on Schedule 14A, filed with the Commission on April 30, 2025);
         
      (b) the Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the Commission on May 7, 2025;
         
      (c) the Registrant’s Current Report on Form 8-K filed with the Commission on June 11, 2025; and
         
      (d) the description of the Registrant’s securities contained in Exhibit 4.1 of the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

     

     

     

     

    All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended, after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement indicating that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of the filing of such documents.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Subject to the foregoing, all information appearing in this Registration Statement is qualified in its entirety by the information appearing in the documents incorporated by reference in this Registration Statement.

     

     

     

     

    Item 8. Exhibits.

     

    The exhibits to this Registration Statement are described below.

     

         
    Exhibit Number   Exhibit
    4.1   Amended Articles of Association of LivaNova PLC, effective as from June 29, 2020 (incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q, filed on July 29, 2020 (File No. 001-37599))
         
    5.1   Opinion of Cleary Gottlieb Steen & Hamilton LLP
         
    10.1   Second Amended and Restated LivaNova PLC 2022 Incentive Award Plan, dated April 23, 2025  (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on June 11, 2025 (Commission File No. 001-37599))
         
    10.5   LivaNova PLC 2025 Director Incentive Award Plan, dated April 23, 2025  (incorporated herein by reference to Exhibit 10.5 to the Registrant’s Current Report on Form 8-K, filed on June 11, 2025 (Commission File No. 001-37599))
         
    23.1   Consent of Cleary Gottlieb Steen & Hamilton LLP (included in Exhibit 5.1)
         
    23.2   Consent of PricewaterhouseCoopers LLP
         
    24.1   Power of Attorney (included on the signature page hereto)
         
    107   Filing Fee Table

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in London, United Kingdom, on June 12, 2025.

     

      LivaNova PLC
         
      By: /s/ Vladimir Makatsaria
        Vladimir Makatsaria
        Chief Executive Officer

     

     

     

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Michael Hutchinson and Sarah Mohr as his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments or any abbreviated registration statement and any amendments thereto filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, increasing the number of securities for which registration is sought), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorney-in-fact, proxy, and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact, proxy and agent, or his substitute, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

     

     

     

    Signature   Title   Date
    /s/ Vladimir Makatsaria  

    Director and Chief Executive Officer

    (Principal Executive Officer)

      June 12, 2025
    Vladimir Makatsaria        
             
    /s/ Alex Shvartsburg  

    Chief Financial Officer

    (Principal Accounting and Financial Officer)

      June 12, 2025
    Alex Shvartsburg        
             
    /s/ William A. Kozy   Chair of the Board of Directors   June 12, 2025
    William A. Kozy        
             
    /s/ J. Christopher Barry   Director   June 12, 2025
    J. Christopher Barry        
             
    /s/ Francesco Bianchi   Director   June 12, 2025
    Francesco Bianchi        
             
    /s/ Stacy Enxing Seng   Director   June 12, 2025
    Stacy Enxing Seng        
             
    /s/ Sharon O’Kane   Director   June 12, 2025
    Sharon O’Kane        
             
    /s/ Susan Podlogar   Director   June 12, 2025
    Susan Podlogar        
             
    /s/ Todd C. Schermerhorn   Director   June 12, 2025
    Todd C. Schermerhorn        
             
    /s/ Brooke Story   Director   June 12, 2025
    Brooke Story        
             
    /s/ Peter Wilver   Director   June 12, 2025
    Peter Wilver        
             
    /s/ Lindsey R. Little   Authorized Representative in the United States   June 12, 2025
    Lindsey R. Little        
             

     

     

     

     

    Get the next $LIVN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LIVN

    DatePrice TargetRatingAnalyst
    5/20/2025$60.00Peer Perform → Outperform
    Wolfe Research
    2/26/2025Outperform → Peer Perform
    Wolfe Research
    10/4/2024$65.00Buy
    Goldman
    9/17/2024$55.00 → $66.00Neutral → Outperform
    Robert W. Baird
    3/20/2024Buy
    Needham
    2/20/2024$60.00 → $70.00Neutral → Buy
    Mizuho
    9/6/2023$52.00Hold
    HSBC Securities
    7/19/2023$56.00Neutral
    Robert W. Baird
    More analyst ratings